Autobio Diagnostics Co., Ltd. (SHA:603658)

Market Cap	19.37B -19.2%
Revenue (ttm)	4.22B -3.5%
Net Income	1.03B -9.3%
EPS	1.81 -8.6%
Shares Out	571.42M
PE Ratio	18.73
Forward PE	17.01
Dividend	1.31 (3.87%)
Ex-Dividend Date	May 26, 2025

Volume	2,263,488
Average Volume	2,109,061
Open	34.53
Previous Close	34.41
Day's Range	33.84 - 34.53
52-Week Range	32.55 - 42.75
Beta	0.06
RSI	47.05
Earnings Date	Apr 23, 2026

About Autobio Diagnostics

Autobio Diagnostics Co., Ltd. engages in the research and development, production, marketing, sale, and service of clinical diagnostic products in China and internationally. The company offers immunoassay, biochemistry, and microbiology products; reagents and instruments; and technical and support, and training services, as well as engages in biology research and development activities. Its immunoassay products consist of AutoLumo S900 and AutoLumo A1860 that provides user experience for small and medium size labs; AutoLumo A6200/A6600, an auto...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1998
• Employees: 5,773
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603658

Financial Performance

In 2025, Autobio Diagnostics's revenue was 4.23 billion, a decrease of -5.47% compared to the previous year's 4.47 billion. Earnings were 1.07 billion, a decrease of -10.59%.